WO2008016356A3 - Genemap of the human genes associated with psoriasis - Google Patents

Genemap of the human genes associated with psoriasis Download PDF

Info

Publication number
WO2008016356A3
WO2008016356A3 PCT/US2006/030281 US2006030281W WO2008016356A3 WO 2008016356 A3 WO2008016356 A3 WO 2008016356A3 US 2006030281 W US2006030281 W US 2006030281W WO 2008016356 A3 WO2008016356 A3 WO 2008016356A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
genemap
genes associated
human genes
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/030281
Other languages
French (fr)
Other versions
WO2008016356A2 (en
Inventor
Abdelmajid Belouchi
John Verner Raelson
Walter Edward Bradley
Bruno Paquin
Quynh Nguyen-Huu
Pascal Croteau
Rene Allard
Randall David Little
Johanne Cousineau
Sophie Debrus
Tim Keith
Natali Henderson
Daniel Dubois
Eerdewegh Paul Van
Jonathan Segal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genizon Biosciences Inc
Original Assignee
Genizon Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genizon Biosciences Inc filed Critical Genizon Biosciences Inc
Priority to US12/309,878 priority Critical patent/US20100120627A1/en
Priority to EP06813283A priority patent/EP2052088A2/en
Priority to PCT/US2006/030281 priority patent/WO2008016356A2/en
Publication of WO2008016356A2 publication Critical patent/WO2008016356A2/en
Anticipated expiration legal-status Critical
Publication of WO2008016356A3 publication Critical patent/WO2008016356A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to psoriasis disease and/or their response to a particular drug or drugs.
PCT/US2006/030281 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis Ceased WO2008016356A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/309,878 US20100120627A1 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis
EP06813283A EP2052088A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis
PCT/US2006/030281 WO2008016356A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/030281 WO2008016356A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis

Publications (2)

Publication Number Publication Date
WO2008016356A2 WO2008016356A2 (en) 2008-02-07
WO2008016356A3 true WO2008016356A3 (en) 2009-04-23

Family

ID=38997596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/030281 Ceased WO2008016356A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis

Country Status (3)

Country Link
US (1) US20100120627A1 (en)
EP (1) EP2052088A2 (en)
WO (1) WO2008016356A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831370A4 (en) * 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES PARTICIPATING IN BONE REMODELING
EP1989328A4 (en) * 2006-02-23 2009-07-01 Univ Johns Hopkins DIAGNOSTIC METHODS RELATED TO BBS10 AND REAGENTS FOR BARDET-BIEDL SYNDROME
ES2444695T3 (en) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polynucleotides and polypeptides involved in cancer
US20120128661A1 (en) * 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US20110311539A1 (en) * 2007-09-17 2011-12-22 Ludwig Institute For Cancer Research Ltd Diagnosis and treatment of cancer using cancer-testis antigens
AU2009227206A1 (en) * 2008-03-18 2009-09-24 Kurume University Polypeptide and pharmaceutical composition containing the polypeptide
US20110229498A1 (en) * 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2123748A1 (en) * 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
WO2009152247A2 (en) 2008-06-11 2009-12-17 Atyr Pharma, Inc Thrombopoietic activity of tyrosyl-trna synthetase polypeptides
CN102159708B (en) * 2008-06-26 2016-08-31 Atyr医药公司 Compositions and methods comprising glycyl-tRNA synthetases having unconventional biological activities
EP2328911A4 (en) 2008-09-22 2012-03-14 Cedars Sinai Medical Center HUMAN MD-2 IN SHORT FORM AS NEGATIVE REGULATOR OF TOLL-4 TYPE RECEIVER SIGNALING
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
EP2186821A1 (en) * 2008-11-11 2010-05-19 Universität Ulm Protein with promoting effects for axonal growth of neurons of central nervous system
WO2010088276A2 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Polynucleotide aptamer-based cross -linked materials and uses thereof
EP2403864B1 (en) 2009-02-27 2015-08-12 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
GB0904382D0 (en) * 2009-03-13 2009-04-29 Univ Dundee Treatment of cell proliferation and differentiation disorders
AU2010226726B8 (en) 2009-03-16 2014-08-14 Pangu Biopharma Limited Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US20100310576A1 (en) 2009-03-31 2010-12-09 Adams Ryan A COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
EP2421991B1 (en) * 2009-04-20 2015-11-11 Lan Ko Breast cancer susceptibility gene gt198 and uses thereof
EP2438170A4 (en) * 2009-06-05 2012-12-26 Univ North Carolina SOGA POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
JP5695384B2 (en) 2009-10-05 2015-04-01 花王株式会社 Hair shape susceptibility gene
JP5695385B2 (en) 2009-10-05 2015-04-01 花王株式会社 Hair shape susceptibility gene
JP5695383B2 (en) 2009-10-05 2015-04-01 花王株式会社 Hair shape susceptibility gene
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
AU2011248521B2 (en) 2010-04-27 2017-03-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases
US20170260235A1 (en) 2010-04-27 2017-09-14 Chanel Parfums Beaute Polypeptide expressed in the stratum corneum and use thereof
FR2959230B1 (en) 2010-04-27 2016-03-25 Chanel Parfums Beaute POLYPEPTIDE EXPRESSED IN CORNEA LAYER AND USE THEREOF
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CN103097524B (en) 2010-04-28 2016-08-03 Atyr医药公司 The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Alanyl-tRNA synthetase finds
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
EP2566516B1 (en) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
ES2668207T3 (en) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic and antibody compositions related to fragments of methionyl-tRNA synthetases proteins
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103096925A (en) 2010-05-03 2013-05-08 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases
CN103096909A (en) 2010-05-04 2013-05-08 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases
JP6008844B2 (en) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of the p38 MULTI-tRNA synthetase complex
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CN103096913B (en) 2010-05-27 2017-07-18 Atyr 医药公司 Treatment, diagnosis and the innovation of antibody compositions related to the protein fragments of glutaminyl tRNA synzyme is found
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
KR20180059575A (en) 2010-07-12 2018-06-04 에이티와이알 파마, 인코포레이티드 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
KR20130102534A (en) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (en) 2010-08-25 2013-05-15 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
CN103118696B (en) 2010-10-06 2020-02-14 Atyr 医药公司 Therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
WO2012051568A1 (en) * 2010-10-14 2012-04-19 Translational Genomics Research Institute Identification and treatment of cancer subsets
FR2968560A1 (en) * 2010-12-13 2012-06-15 Oreal USE OF THE IDE AS A BIOMARKER OF A CONDITION OF THE SCALP
SI3173427T1 (en) 2011-03-31 2019-08-30 ADC Therapeutics SA, Antibodies to the kidney-bound antigen 1 and antigen-binding fragments thereof
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
KR102102239B1 (en) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 Method for treating breast cancer
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
NZ703724A (en) 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6259983B2 (en) * 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Th1 cell KIF20A epitope peptide and vaccine containing the same
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
GB201223114D0 (en) * 2012-12-21 2013-02-06 Nat Univ Ireland Novel peptide
ES2708565T3 (en) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugates of Fc-histidyl-tRNA synthetase
EP3461909A1 (en) * 2013-05-21 2019-04-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
US20160143256A1 (en) * 2013-07-10 2016-05-26 Joseph A. MAJZOUB Mrap2 knockouts
CN105745224B (en) 2013-10-11 2019-11-05 牛津生物疗法有限公司 Conjugated antibodies against LY75 for the treatment of cancer
LT3388075T (en) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES3034857T3 (en) * 2015-11-12 2025-08-25 The Res Institute At Nationwide Childrens Hospital Methods of treating muscular dystrophy
KR102877920B1 (en) 2015-11-16 2025-10-30 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Materials and methods for the treatment of titin-based myopathy and other titinopathies
WO2017096375A1 (en) * 2015-12-04 2017-06-08 New York University Identification of epilepsy patients at increased risk from sudden unexpected death in epilepsy
HRP20210698T1 (en) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
CN116284392A (en) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 Activin type 2 receptor binding proteins and uses thereof
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN110891596A (en) 2017-05-04 2020-03-17 希望之城 Antibody variable domains and antibody constructs
AR114350A1 (en) 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital GENETIC THERAPY FOR TYPE 2C MUSCULAR WAIST DYSTROPHY
KR20210028162A (en) 2018-06-29 2021-03-11 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Recombinant adeno-associated virus products and methods for the treatment of rhomboid muscle dystrophy type 2A
BR112021006941A2 (en) 2018-10-19 2021-08-31 The Francis Crick Institute Limited INNOVATIVE CANCER ANTIGENS AND METHODS
AU2020229340A1 (en) 2019-02-26 2021-09-16 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy
EP3745404B1 (en) * 2019-05-29 2024-04-03 Cell Networks GmbH Method and system for predicting coupling probabilities of g-protein coupled receptors with g-proteins
CN112080559B (en) * 2019-06-14 2023-09-01 复旦大学附属华山医院 Application of SNP locus of PPP1CB gene in preparation of product for detecting susceptibility to psoriasis vulgaris
CA3144054A1 (en) 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
EP3994156A1 (en) * 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
RS65421B1 (en) 2019-08-21 2024-05-31 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
DK4034170T3 (en) 2019-10-23 2026-03-30 Cue Biopharma Inc TGF-BETA POLYPEPTIDES
CA3165449A1 (en) * 2019-12-24 2021-07-01 Dyve Biosciences, Inc. Topical cyclosporine for treating psoriasis and other ailments
US20230218731A1 (en) * 2020-05-26 2023-07-13 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
CN116782827A (en) * 2020-11-30 2023-09-19 明德拉公司 Microneedle devices and methods and skin condition determination
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
CA3216273A1 (en) * 2021-04-21 2022-10-27 Ronald D. SEIDEL III Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
WO2023283194A2 (en) * 2021-07-05 2023-01-12 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Method for cold plasma-induced cell death in breast cancer cells by 8-oxog modification and degradation of histone mrna
EP4219726A1 (en) 2021-10-15 2023-08-02 Research Institute at Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
CN115381951A (en) * 2022-09-28 2022-11-25 孙良丹 Use of VEGF gene expression inhibitors in the preparation or as a formulation for the treatment of psoriasis
CN116407636B (en) * 2023-05-15 2023-10-20 徐州医科大学附属医院 Application of Lnc-CCKAR-5 in preparation of medicine for promoting diabetic wound repair
WO2025213184A1 (en) * 2024-04-05 2025-10-09 Fred Hutchinson Cancer Center Novel tcrs and neoantigens in srsf2 and zrsr2 mutated cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Affymetrix: Details for HG-U95C:65653_AT", 2 June 2008 (2008-06-02), XP008116284, Retrieved from the Internet <URL:affymetrix.com> *
WRIGHT, ALAN ET AL.: "Population choice in mapping genes for complex diseases.", NATURE GENETICS., vol. 23, 1999, pages 397 - 404, XP008107916 *
ZHOU, XIANGHONG ET AL.: "Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100 element oligonucleotide array.", PHYSIOLOGICAL GENOMICS., vol. 13, 2003, pages 69 - 78, XP002512061 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US9995755B2 (en) 2010-12-16 2018-06-12 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US11226341B2 (en) 2010-12-16 2022-01-18 Genentech, Inc. Method of treating asthma using an IL-13 antibody

Also Published As

Publication number Publication date
EP2052088A2 (en) 2009-04-29
US20100120627A1 (en) 2010-05-13
WO2008016356A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2008016356A3 (en) Genemap of the human genes associated with psoriasis
WO2008112177A3 (en) Genemap of the human genes associated with schizophrenia
WO2008118258A3 (en) Genemap of the human genes associated with adhd
WO2008067195A3 (en) Genemap of the human genes associated with crohn&#39;s disease
WO2007025085A3 (en) Genemap of the human genes associated with crohn&#39;s disease
WO2009026116A3 (en) Genemap of the human genes associated with longevity
WO2006138696A3 (en) Genemap of the human genes associated with longevity
WO2008085601A3 (en) Genemap of the human genes associated with asthma disease
WO2009039244A3 (en) Genemap of the human genes associated with crohn&#39;s disease
WO2008014400A3 (en) Crohn disease susceptibility gene
EP2581453A3 (en) Genetic Markers of Mental Illness
WO2004005458A3 (en) Functional sites
EP2570498A3 (en) Genetic markers of mental illness
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
EP2540840A3 (en) Genetic variants on CHR16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008123901A3 (en) Genemap of the human genes associated with endometriosis
EP2639317A3 (en) Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2009064973A3 (en) Diagnostic kits and methods for scd or sca therapy selection
WO2008055196A3 (en) Genemap of the human genes associated with male pattern baldness
WO2006081158A3 (en) Predictive and therapeutic markers in overian cancer
WO2011066082A3 (en) Markers associated with ribavirin-induced anemia
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer&#39;s disease
WO2006063703A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2006086748A3 (en) Genetic markers in the csf2rb gene associated with an adverse hematological response to drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06813283

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006813283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12309878

Country of ref document: US